Brief: CASI Pharmaceuticals And Bioinvent Announce CTA Approval For Clinical Study Of BI-1206 In NHL In China

BioInvent International AB

10/12/2021 12:06

Dec 10 (Reuters) - CASI Pharmaceuticals, Inc.  CASI.O :
    * CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE CTA APPROVAL
FOR
CLINICAL STUDY OF BI-1206 IN NHL IN CHINA
    * CASI PHARMACEUTICALS INC - NMPA APPROVED BI-1206 CTA A
NOVEL
ANTI-FCΓRIIB
    * CASI PHARMACEUTICALS INC - TRIALS EXPECTED TO ENROLL
PATIENTS
STARTING IN 1H 2022

Source text for Eikon:  ID:nPn2dK88ma 
Further company coverage:  CASI.O 

 ((Reuters.Briefs@thomsonreuters.com;;))